Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-04 | 2024-09 | -0.03 | N/A | N/A | N/A |
2024-08-05 | 2024-06 | -0.04 | 0.01 | 0.05 | 125.00% |
2024-05-07 | 2024-03 | -0.07 | N/A | N/A | N/A |
2024-05-07 | 2024-03 | -0.07 | -0.05 | 0.02 | 28.57% |
2024-03-12 | 2023-12 | -0.18 | N/A | N/A | N/A |
2024-03-12 | 2023-12 | -0.18 | -0.12 | 0.06 | 33.33% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-10 | Citigroup | Upgrade | Neutral | Neutral |
2023-03-05 | Canaccord Genuity | Upgrade | Buy | |
2023-03-05 | Credit Suisse | Upgrade | Underperform | |
2022-11-15 | Citigroup | Upgrade | Neutral | |
2022-11-07 | SVB Leerink | Upgrade | Market Perform | |
2022-08-08 | Citigroup | Upgrade | Neutral |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-01-02 | CLINTON CHELSEA | Director | 541.84K | Stock Award(Grant) |
2024-01-02 | EDWARDS CARLADENISE ARMBRISTER | Director | 412.25K | Stock Award(Grant) |
2024-08-08 | GARIPALLI VIVEK | Director and Beneficial Owner of more than 10% of a Class of Security | 1.41M | Purchase |
2024-01-02 | KOUZOUKAS DEMETRIOS L | Director | 465.64K | Stock Award(Grant) |
2024-05-16 | LOENGARD ANNA U | Director | 0.00 | Purchase |
2024-09-12 | REYNOSO JAMIE L. | Officer | 2.75M | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 31.43M | 28.20M | 7.92% |
2023-06-29 | Renaissance Technologies, LLC | 8.85M | 7.94M | 2.23% |
2023-06-29 | Blackrock Inc. | 7.77M | 6.97M | 1.96% |
2023-06-29 | Citadel Advisors Llc | 5.35M | 4.80M | 1.35% |
2023-06-29 | PNC Financial Services Group, Inc. | 5.26M | 4.72M | 1.33% |
2023-06-29 | Millennium Management Llc | 4.65M | 4.17M | 1.17% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 10.28M | 9.22M | 2.59% |
2023-06-29 | Vanguard Small-Cap Index Fund | 9.15M | 8.21M | 2.30% |
2023-06-29 | Vanguard Small-Cap Growth Index Fund | 5.24M | 4.70M | 1.32% |
2023-06-29 | Vanguard Extended Market Index Fund | 4.77M | 4.28M | 1.20% |
2023-05-30 | Fidelity Extended Market Index Fund | 1.70M | 1.44M | 0.43% |
2023-05-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 1.37M | 1.16M | 0.34% |
-
Close the f@ckin market
-
Great buying opportunity will ride this u til $18-20 now
$CLOV go go
-
Probably they didn’t make any PR because of silent period after ipo’ed??
As you can see the start to show the earnings and the showcase of clover health software in March. -
Next week would be my last holding this shit
-
Fucking 10.50 wall
-
What load?? It’s been like this playing between (.40-.10) for a week now.
-
POS.......
-
I want to die
-
Gme will make the market down again
-
Imagine if you invested in $CLOV and $CCIV!
Lol -
Wtf with the market man!! It was green few hours ago!
-
I’m not going to watch the market, most likely red. We’re going sub 9. See you at the earnings . GL.
-
Clov is not a bio tech bro
-
Phew! Almost had a heart attack when it went sub 10. lol
-
$CLOV Biden’s America
-
Close above 11
-
POS .....
-
Back to red again
-
5$ it will close red
-
I want to die again
-
Clover Health Investments (NASDAQ:CLOV) Stock Price Up 6.4%
news.google.com • -
Clover Health to Participate in Upcoming 2024 Wells Fargo Healthcare Conference
globenewswire.com • -
CLOV Stock Alert: What to Know About Clover Health's Big Insider Buy
investorplace.com • -
3 Healthcare AI Stocks Positioned for Potential Breakthroughs
investorplace.com • -
Clover Health Investments, Corp. (CLOV) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
Clover Health to Report Second Quarter 2024 Financial Results on August 5
globenewswire.com • -
Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement
globenewswire.com • -
The 'Undercovered' Dozen From June 1-6
seekingalpha.com • -
Clover Health: New Business Model Is A Game Changer
seekingalpha.com •